LabGenomics, Key Executives Increase Insider Buying... Confidence in Enhancing Corporate Value

Genome molecular diagnostics specialist LabGenomics announced on the 20th that two executives have conducted insider purchases.

Junghee Cho, Executive Director and Head of the Global Business Division as well as the Head of the U.S. subsidiary, and Sook Kim, Director and Head of the NGS (Next-Generation Sequencing) Lab Division, each purchased stocks worth 100 million KRW.

A company representative stated, "The stock purchases were made with confidence that corporate value will be enhanced following entry into the U.S. market," adding, "We will strive to become a global diagnostic company through responsible management and active research and development."

On the 17th, LabGenomics announced an investment of 76 billion KRW in its U.S. subsidiary, LabGenomicsUSA. Using this, they plan to acquire a large CLIA lab ranked within the top 100 in the U.S.

'CLIA' is a standard certification system by the U.S. FDA (Food and Drug Administration) that verifies the accuracy and reliability of laboratories conducting clinical tests for disease diagnosis, prevention, and treatment. Utilizing a CLIA-certified lab allows the export of diagnostic services and products that have not received FDA approval.

This content was produced with the assistance of AI translation services.